US 12,312,409 B2
Bispecific CD137-binding antibodies for T-cell activation
Jhong-Jhe You, Taipei (TW); Ching-Hsuan Hsu, Taoyaun (TW); Po-Lin Huang, Taipei (TW); and Jeng-Horng Her, San Jose, CA (US)
Assigned to AP Biosciences, Inc., Taipei (TW)
Filed by AP Biosciences, Inc., Taipei (TW)
Filed on Jul. 17, 2023, as Appl. No. 18/222,763.
Application 18/222,763 is a division of application No. 16/911,052, filed on Jun. 24, 2020, granted, now 11,725,058.
Claims priority of provisional application 62/953,302, filed on Dec. 24, 2019.
Claims priority of provisional application 62/866,699, filed on Jun. 26, 2019.
Prior Publication US 2024/0026018 A1, Jan. 25, 2024
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2878 (2013.01) [C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01)] 9 Claims
OG exemplary drawing
 
1. A bispecific antibody comprising a first antigen binding region and a second antigen binding region,
wherein the first antigen binding region binds to CD137, and
wherein the first antigen binding region comprises:
(i) heavy chain variable (VH) complementarity determining region (CDR)-H1, CDR-H2, and CDR-H3, wherein CDR-H1 comprises the amino acid sequence of SEQ ID NO:19, CDR-H2 comprises the amino acid sequence of SEQ ID NO:20, and CDR-H3 comprises the amino acid sequence of SEQ ID NO:21; and
(ii) light chain variable (VL) CDR-L1, CDR-L2, and CDR-L3, wherein CDR-L1 comprises the amino acid sequence of SEQ ID NO:22, CDR-L2 comprises the amino acid sequence of SEQ ID NO:23, and CDR-L3 comprises the amino acid sequence of SEQ ID NO:24.